Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

ABSTRACT:

Background

Due to the number of emerging new treatment options, the systemic treatment of hepatocellular carcinoma (HCC) is rapidly changing. We provide here an overview of the current landscape of systemic treatment of HCC and discuss its potential future development.

Summary

HCC is a leading cause of tumor-related death worldwide. Despite the efforts aimed at reducing the prevalence of HCC through vaccination and antiviral treatment, and the implementation of screening programs for early tumor detection, most patients are diagnosed with or progress to advanced HCC. For approximately 10 years, sorafenib has been the only effective systemic treatment available for these patients. Recently, however, a number of new systemic compounds, comprising several multi-kinase inhibitor

SUBMITTER: Reiter FP 

PROVIDER: S-EPMC9501734 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature